

Elisabetta Vergani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/808434/publications.pdf>

Version: 2024-02-01

24
papers

858
citations

840776

11
h-index

677142

22
g-index

24
all docs

24
docs citations

24
times ranked

1864
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. <i>Journal of Clinical Investigation</i> , 2018, 128, 5505-5516.	8.2	193
2	TNF-Related Apoptosis-Inducing Ligand (TRAIL)–Armed Exosomes Deliver Proapoptotic Signals to Tumor Site. <i>Clinical Cancer Research</i> , 2016, 22, 3499-3512.	7.0	158
3	Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032. <i>Neoplasia</i> , 2011, 13, 1132-IN17.	5.3	89
4	Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. <i>Oncotarget</i> , 2016, 7, 4428-4441.	1.8	84
5	Alternative Activation of Human Plasmacytoid DCs In Vitro and in Melanoma Lesions: Involvement of LAG-3. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1893-1902.	0.7	74
6	Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 407-420.	2.8	39
7	Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 12857-12868.	1.8	32
8	Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression. <i>Cancer Research</i> , 2014, 74, 130-140.	0.9	27
9	Extracellular vesicles in anti-tumor immunity. <i>Seminars in Cancer Biology</i> , 2022, 86, 64-79.	9.6	21
10	Targeting Immune Regulatory Networks to Counteract Immune Suppression in Cancer. <i>Vaccines</i> , 2016, 4, 38.	4.4	20
11	miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFκB-mediated inflammatory mediators. <i>Cell Communication and Signaling</i> , 2020, 18, 156.	6.5	18
12	The Fatty Acid and Protein Profiles of Circulating CD81-Positive Small Extracellular Vesicles Are Associated with Disease Stage in Melanoma Patients. <i>Cancers</i> , 2021, 13, 4157.	3.7	17
13	Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma. <i>Cancer Research</i> , 2020, 80, 2676-2688.	0.9	14
14	Deregulated FASN Expression in BRAF Inhibitor-Resistant Melanoma Cells Unveils New Targets for Drug Combinations. <i>Cancers</i> , 2021, 13, 2284.	3.7	13
15	microRNAs Shape Myeloid Cell-Mediated Resistance to Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 1214.	4.8	12
16	Network modeling of patients' biomolecular profiles for clinical phenotype/outcome prediction. <i>Scientific Reports</i> , 2020, 10, 3612.	3.3	11
17	Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	3.7	10
18	microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response. <i>Genes</i> , 2016, 7, 124.	2.4	8

#	ARTICLE	IF	CITATIONS
19	Identification of suitable mRNAs and microRNAs as reference genes for expression analyses in skin cells under sex hormone exposure. <i>Gene</i> , 2021, 769, 145336.	2.2	7
20	Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles. <i>Journal of Investigative Dermatology</i> , 2022, 142, 3030-3040.e5.	0.7	6
21	Genetic Variants and Somatic Alterations Associated with MITF-E318K Germline Mutation in Melanoma Patients. <i>Genes</i> , 2021, 12, 1440.	2.4	2
22	Enhancer of zeste 2 polycomb repressive complex 2 subunit polymorphisms in melanoma skin cancer risk. <i>Experimental Dermatology</i> , 2020, 29, 980-986.	2.9	1
23	Selective modulation of immune transcripts in extracellular vesicles from plasma of renal cell carcinoma patients receiving nivolumab.. <i>Journal of Clinical Oncology</i> , 2020, 38, 719-719.	1.6	1
24	3D models for melanoma T cell-based immunotherapy. <i>Clinical and Translational Medicine</i> , 2022, 12, .	4.0	1